+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Modafinil Oral Drugs Market - Global Forecast 2026-2032- Product Image
Modafinil Oral Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Modafinil Oral Drugs Market - Global Forecast 2026-2032

  • Report

  • 198 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6140193
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Modafinil Oral Drugs Market is projected to reach USD 1.51 Billion in 2026. It is expected to continue growing at a CAGR of 8.32%, reaching USD 2.48 Billion by 2032.

Modafinil Oral Drugs: Executive Overview

Modafinil oral drugs are prescription medicines used primarily to promote wakefulness in conditions such as narcolepsy, obstructive sleep apnea-related excessive sleepiness, and shift work sleep disorder, subject to local approvals and labeling. Their clinical value is linked to improved daytime alertness, while prescribing requires attention to contraindications, drug interactions, psychiatric effects, cardiovascular considerations, and the potential for misuse or diversion. The market is shaped by medical-need recognition, regulatory controls, generic availability, reimbursement policies, and access to sleep-medicine services.

Regulatory Scrutiny and Access Are Reshaping the Landscape

The landscape is evolving through tighter controls on prescription medicines with misuse potential, continued emphasis on pharmacovigilance, and more structured diagnosis of sleep-wake disorders. Generic competition can improve affordability, but access remains uneven where specialist assessment, diagnostic testing, or reimbursement is limited. Clinicians and health systems are also placing greater weight on comprehensive treatment plans that address underlying sleep disorders, adherence, safety monitoring, and behavioral or occupational factors rather than relying on wakefulness-promoting therapy alone.

Artificial Intelligence Strengthens Diagnosis, Safety, and Care Coordination

Artificial intelligence can support the modafinil oral drugs ecosystem by identifying patterns in clinical records, screening for excessive daytime sleepiness, and helping prioritize patients for formal sleep evaluation. Predictive tools may also flag potential drug interactions, adherence concerns, adverse-event signals, and inappropriate prescribing for clinician review. However, AI outputs require validation across populations and health systems, transparent governance, protection of sensitive health data, and human oversight. AI should augment-not replace-clinical diagnosis, individualized prescribing, and post-treatment monitoring.

Regional Insights: Uneven Access and Distinct Regulatory Priorities

North America combines established sleep-medicine infrastructure with strong controlled-substance oversight and heightened attention to appropriate use. Europe emphasizes harmonized safety principles while national reimbursement and prescribing pathways differ across countries. Asia-Pacific presents varied regulatory environments and expanding awareness of sleep disorders, alongside differences in specialist capacity and medicine access. Latin America is influenced by affordability, public-sector procurement, and uneven diagnostic coverage. The Middle East is seeing greater focus on sleep health in settings affected by shift work and chronic disease, while access and regulatory implementation vary. Africa faces substantial gaps in specialist services, diagnostic capacity, and medicine availability, making primary-care recognition and referral pathways particularly important.

Group Insights: Cooperation Shapes Standards, Access, and Supply

ASEAN markets reflect diverse regulatory systems, healthcare capacity, and reimbursement arrangements, creating a need for adaptable registration and education strategies. BRICS countries combine large and varied patient populations with different approaches to generic medicines, domestic production, and controlled-drug governance. The European Union benefits from shared regulatory structures while retaining national differences in reimbursement and clinical practice. G7 countries generally have mature pharmacovigilance and specialist-care systems, although affordability and equitable access remain relevant. GCC members often have well-resourced urban healthcare networks but differing national formularies and reliance on imported medicines. NATO countries span multiple healthcare models, so the group is better understood through common attention to supply resilience, safety, and continuity of care than through a single market pathway.

Country Insights: Policy and Care Pathways Differ Across Major Markets

Australia emphasizes regulated prescribing and specialist assessment within a universal healthcare framework. Brazil and Mexico continue to face variation in diagnostic access and affordability across public and private care. Canada and the United States have developed sleep-medicine services but maintain close controls around prescribing, reimbursement, and monitoring. China and India combine growing clinical awareness with substantial regional variation in specialist capacity and medicine access. Japan and South Korea emphasize structured healthcare delivery and aging-population needs, with local regulatory requirements influencing use. France, Germany, Italy, and Spain operate within European safety frameworks while differing in reimbursement, formularies, and referral practices. The United Kingdom combines national guidance with controlled prescribing and centralized health-system processes. Russia’s access, supply, and regulatory conditions are shaped by domestic policy and healthcare-system factors.

Action Priorities for Safer, More Effective Industry Participation

Industry leaders should prioritize evidence-based education for clinicians and patients, with clear differentiation between approved indications and unsupported performance uses. Strengthening pharmacovigilance, medication-authentication measures, responsible distribution, and adherence support can reduce avoidable harm and diversion. Partnerships with sleep specialists, primary-care networks, payers, and public-health bodies can improve diagnosis and continuity of care. Organizations should also design region-specific access strategies that account for local formularies, reimbursement, controlled-medicine requirements, and supply-chain resilience. AI investments should focus on validated clinical workflows, explainable alerts, privacy protection, and measurable improvements in safety and patient outcomes.

Research Methodology: Evidence-Based Multidimensional Assessment

This executive summary uses a structured assessment of modafinil oral drugs across clinical use, regulation, access, healthcare infrastructure, safety, technology, and regional policy conditions. The analysis compares North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific, and integrates perspectives from ASEAN, BRICS, the European Union, G7, GCC, and NATO. Country-level interpretation covers Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Russia, South Korea, Spain, the United Kingdom, and the United States. Findings are framed qualitatively and avoid market estimates, market shares, forecasts, and unsupported claims; local prescribing information and current regulatory guidance should be consulted for operational decisions.

Conclusion: Responsible Access and Clinical Stewardship Are Central

The future of modafinil oral drugs will depend less on product availability alone than on accurate diagnosis, appropriate prescribing, dependable supply, and sustained safety monitoring. Regional and country differences require tailored approaches, while group-level cooperation can support consistent quality and stronger pharmacovigilance. Leaders who align innovation, including carefully governed AI, with clinical evidence and responsible access will be better positioned to support patients with legitimate wakefulness needs while limiting misuse and avoidable risk.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Modafinil Oral Drugs Market, by Product Type
7.1. Introduction
7.2. Brand
7.3. Generic
8. Modafinil Oral Drugs Market, by Dosage Strength
8.1. Introduction
8.2. 100 Mg
8.3. 200 Mg
9. Modafinil Oral Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Modafinil Oral Drugs Market, by Application
10.1. Introduction
10.2. Cognitive Enhancement
10.3. Narcolepsy
10.4. Shift Work Sleep Disorder
11. Modafinil Oral Drugs Market, by End-User
11.1. Introduction
11.2. Clinics
11.3. Home Care
11.4. Hospitals
12. Modafinil Oral Drugs Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Modafinil Oral Drugs Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Modafinil Oral Drugs Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Alembic Pharmaceuticals Ltd.
16.2. Apotex Inc.
16.3. Auro Laboratories
16.4. Aurobindo Pharma Ltd.
16.5. Cephalon Inc.
16.6. Cipla Limited
16.7. Dr. Reddy’s Laboratories Ltd.
16.8. FDC Limited
16.9. Glenmark Pharmaceuticals Ltd.
16.10. HAB Pharmaceuticals
16.11. Hetero Healthcare Ltd.
16.12. Intas Pharmaceuticals Ltd.
16.13. Lupin Limited
16.14. Mylan N.V.
16.15. Orbion Pharmaceuticals
16.16. Sandoz International GmbH
16.17. Seqens
16.18. Sun Pharmaceutical Industries Ltd.
16.19. Sunrise Pharma
16.20. Teva Pharmaceutical Industries Ltd.
16.21. Torrent Pharmaceuticals Ltd.
16.22. Watson Labs
16.23. Wockhardt Ltd.
16.24. Xiangbei Welman Pharmaceutical Co., Ltd.
16.25. Zydus Cadila Healthcare Ltd.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Modafinil Oral Drugs Market, Years Considered for the Study
FIGURE 2. Global Modafinil Oral Drugs Market, Research Design
FIGURE 3. Global Modafinil Oral Drugs Market, Research Framework
FIGURE 4. Global Modafinil Oral Drugs Market, Data Triangulation
FIGURE 5. Global Modafinil Oral Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Modafinil Oral Drugs Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Modafinil Oral Drugs Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Modafinil Oral Drugs Market Size, by Dosage Strength, 2025 vs 2032 (%)
FIGURE 9. Global Modafinil Oral Drugs Market Size, by Dosage Strength, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Modafinil Oral Drugs Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 11. Global Modafinil Oral Drugs Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Modafinil Oral Drugs Market Size, by Application, 2025 vs 2032 (%)
FIGURE 13. Global Modafinil Oral Drugs Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Modafinil Oral Drugs Market Size, by End-User, 2025 vs 2032 (%)
FIGURE 15. Global Modafinil Oral Drugs Market Size, by End-User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Modafinil Oral Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Modafinil Oral Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Modafinil Oral Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Modafinil Oral Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Modafinil Oral Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Modafinil Oral Drugs Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Modafinil Oral Drugs Market Segmentation & Coverage
TABLE 2. Global Modafinil Oral Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Brand Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Brand Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Brand Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Generic Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Generic Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Generic Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 11. Global 100 Mg Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global 100 Mg Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global 100 Mg Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global 200 Mg Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global 200 Mg Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global 200 Mg Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 18. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 19. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 20. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 21. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 22. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 23. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 24. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 28. Global Cognitive Enhancement Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Cognitive Enhancement Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Cognitive Enhancement Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Narcolepsy Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Narcolepsy Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Narcolepsy Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Shift Work Sleep Disorder Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Shift Work Sleep Disorder Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Shift Work Sleep Disorder Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 38. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Modafinil Oral Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Asia-Pacific Modafinil Oral Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Asia-Pacific Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 50. Asia-Pacific Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 51. Asia-Pacific Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 52. Asia-Pacific Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 53. Asia-Pacific Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 54. North America Modafinil Oral Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. North America Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 56. North America Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 57. North America Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 58. North America Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 59. North America Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 60. Latin America Modafinil Oral Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Latin America Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 62. Latin America Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 63. Latin America Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 64. Latin America Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 65. Latin America Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 66. Europe Modafinil Oral Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Europe Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 68. Europe Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 69. Europe Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 70. Europe Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 71. Europe Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 72. Middle East Modafinil Oral Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Middle East Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 74. Middle East Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 75. Middle East Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 76. Middle East Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 77. Middle East Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 78. Africa Modafinil Oral Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Africa Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 80. Africa Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 81. Africa Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 82. Africa Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 83. Africa Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 84. Global Modafinil Oral Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. ASEAN Modafinil Oral Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. ASEAN Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 87. ASEAN Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 88. ASEAN Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 89. ASEAN Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 90. ASEAN Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 91. GCC Modafinil Oral Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. GCC Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 93. GCC Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 94. GCC Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 95. GCC Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 96. GCC Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 97. European Union Modafinil Oral Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. European Union Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 99. European Union Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 100. European Union Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 101. European Union Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 102. European Union Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 103. BRICS Modafinil Oral Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. BRICS Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 105. BRICS Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 106. BRICS Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 107. BRICS Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 108. BRICS Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 109. G7 Modafinil Oral Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 110. G7 Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 111. G7 Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 112. G7 Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 113. G7 Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 114. G7 Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 115. NATO Modafinil Oral Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. NATO Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 117. NATO Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 118. NATO Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 119. NATO Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 120. NATO Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 121. Global Modafinil Oral Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 122. United States Modafinil Oral Drugs Market Size, 2017-2032 (USD Million)
TABLE 123. United States Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 124. United States Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 125. United States Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 126. United States Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 127. United States Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 128. Canada Modafinil Oral Drugs Market Size, 2017-2032 (USD Million)
TABLE 129. Canada Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 130. Canada Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 131. Canada Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 132. Canada Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 133. Canada Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 134. Mexico Modafinil Oral Drugs Market Size, 2017-2032 (USD Million)
TABLE 135. Mexico Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 136. Mexico Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 137. Mexico Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 138. Mexico Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 139. Mexico Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 140. Brazil Modafinil Oral Drugs Market Size, 2017-2032 (USD Million)
TABLE 141. Brazil Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 142. Brazil Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 143. Brazil Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 144. Brazil Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 145. Brazil Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 146. United Kingdom Modafinil Oral Drugs Market Size, 2017-2032 (USD Million)
TABLE 147. United Kingdom Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 148. United Kingdom Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 149. United Kingdom Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 150. United Kingdom Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 151. United Kingdom Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 152. Germany Modafinil Oral Drugs Market Size, 2017-2032 (USD Million)
TABLE 153. Germany Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 154. Germany Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 155. Germany Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 156. Germany Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 157. Germany Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 158. France Modafinil Oral Drugs Market Size, 2017-2032 (USD Million)
TABLE 159. France Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 160. France Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 161. France Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 162. France Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 163. France Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 164. Russia Modafinil Oral Drugs Market Size, 2017-2032 (USD Million)
TABLE 165. Russia Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 166. Russia Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 167. Russia Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 168. Russia Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 169. Russia Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 170. Italy Modafinil Oral Drugs Market Size, 2017-2032 (USD Million)
TABLE 171. Italy Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 172. Italy Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 173. Italy Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 174. Italy Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 175. Italy Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 176. Spain Modafinil Oral Drugs Market Size, 2017-2032 (USD Million)
TABLE 177. Spain Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 178. Spain Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 179. Spain Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 180. Spain Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 181. Spain Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 182. China Modafinil Oral Drugs Market Size, 2017-2032 (USD Million)
TABLE 183. China Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 184. China Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 185. China Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 186. China Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 187. China Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 188. India Modafinil Oral Drugs Market Size, 2017-2032 (USD Million)
TABLE 189. India Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 190. India Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 191. India Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 192. India Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 193. India Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 194. Japan Modafinil Oral Drugs Market Size, 2017-2032 (USD Million)
TABLE 195. Japan Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 196. Japan Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 197. Japan Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 198. Japan Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 199. Japan Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 200. Australia Modafinil Oral Drugs Market Size, 2017-2032 (USD Million)
TABLE 201. Australia Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 202. Australia Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 203. Australia Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 204. Australia Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 205. Australia Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 206. South Korea Modafinil Oral Drugs Market Size, 2017-2032 (USD Million)
TABLE 207. South Korea Modafinil Oral Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 208. South Korea Modafinil Oral Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 209. South Korea Modafinil Oral Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 210. South Korea Modafinil Oral Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 211. South Korea Modafinil Oral Drugs Market Size, by End-User, 2017-2032 (USD Million)
TABLE 212. Global Modafinil Oral Drugs Market Share, by Key Player, 2025
TABLE 213. Global Modafinil Oral Drugs Market, Key Experts

Companies Mentioned

  • Alembic Pharmaceuticals Ltd.
  • Apotex Inc.
  • Auro Laboratories
  • Aurobindo Pharma Ltd.
  • Cephalon Inc.
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • FDC Limited
  • Glenmark Pharmaceuticals Ltd.
  • HAB Pharmaceuticals
  • Hetero Healthcare Ltd.
  • Intas Pharmaceuticals Ltd.
  • Lupin Limited
  • Mylan N.V.
  • Orbion Pharmaceuticals
  • Sandoz International GmbH
  • Seqens
  • Sun Pharmaceutical Industries Ltd.
  • Sunrise Pharma
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Watson Labs
  • Wockhardt Ltd.
  • Xiangbei Welman Pharmaceutical Co., Ltd.
  • Zydus Cadila Healthcare Ltd.

Related Topics

Related Reports

Modafinil Tablets Market - Global Forecast 2026-2032 - Product Image

Modafinil Tablets Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Modafinil (CAS 68693-11-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Modafinil (CAS 68693-11-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Narcolepsy Drugs Market - Global Forecast 2026-2032 - Product Image

Narcolepsy Drugs Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Excessive Daytime Sleepiness (EDS) - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Excessive Daytime Sleepiness (EDS) - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 205 Pages
  • Global
From
Pharmacological Advances in Central Nervous System Stimulants. Advances in Pharmacology Volume 99 - Product Image

Pharmacological Advances in Central Nervous System Stimulants. Advances in Pharmacology Volume 99

  • Book
Copyright © 2002-2026 Research and Markets. All Rights Reserved.